Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BRAF V600K”

16 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 16 of 16 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT04439279
What this trial is testing

Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 35
Testing effectiveness (Phase 2)Temporarily pausedNCT05756556
What this trial is testing

T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma

Who this might be right for
MelanomaMalignant Melanoma
ImmVira Pharma Co. Ltd 68
Early research (Phase 1)Ended earlyNCT01940809
What this trial is testing

Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery

Who this might be right for
BRAF V600E Mutation PresentBRAF V600K Mutation PresentMetastatic Melanoma+5 more
National Cancer Institute (NCI) 15
Early research (Phase 1)Study completedNCT01767454
What this trial is testing

Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma

Who this might be right for
Solid Tumours
GlaxoSmithKline 38
Testing effectiveness (Phase 2)Ended earlyNCT04310397
What this trial is testing

Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma

Who this might be right for
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8Pathologic Stage IIIC Cutaneous Melanoma AJCC v8Pathologic Stage IIID Cutaneous Melanoma AJCC v8
M.D. Anderson Cancer Center 4
Early research (Phase 1)Ended earlyNCT02097225
What this trial is testing

Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Who this might be right for
BRAF V600E Mutation PresentBRAF V600K Mutation PresentMetastatic Malignant Solid Neoplasm+7 more
National Cancer Institute (NCI) 22
Early research (Phase 1)Looking for participantsNCT03975231
What this trial is testing

Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer

Who this might be right for
BRAF NP_004324.2:p.V600EBRAF V600K Mutation PresentThyroid Gland Anaplastic Carcinoma
City of Hope Medical Center 6
Early research (Phase 1)Ended earlyNCT03878719
What this trial is testing

Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma

Who this might be right for
Melanoma
Pfizer 1
Testing effectiveness (Phase 2)Active Not RecruitingNCT06400225
What this trial is testing

Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmRefractory Lymphoma+2 more
National Cancer Institute (NCI) 35
Testing effectiveness (Phase 2)Study completedNCT06208124
What this trial is testing

IMM-6-415 in RAS/RAF Mutant Solid Tumors

Who this might be right for
Advanced Solid Tumor (Phase 1)Pancreas AdenocarcinomaNon-small Cell Lung Cancer+1 more
Immuneering Corporation 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439292
What this trial is testing

Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 35
Large-scale testing (Phase 3)Study completedNCT01909453
What this trial is testing

Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma

Who this might be right for
Melanoma
Pfizer 921
Testing effectiveness (Phase 2)Study completedNCT02039947
What this trial is testing

Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain

Who this might be right for
Melanoma and Brain Metastases
Novartis Pharmaceuticals 127
Testing effectiveness (Phase 2)Ended earlyNCT03973918
What this trial is testing

Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG

Who this might be right for
High Grade GliomaBRAF V600EBRAF V600K+4 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 5
Testing effectiveness (Phase 2)Ended earlyNCT01978236
What this trial is testing

Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites

Who this might be right for
Melanoma and Brain Metastases
GlaxoSmithKline 6
Early research (Phase 1)Ended earlyNCT04294160
What this trial is testing

Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer

Who this might be right for
BRAF V600 Colorectal Cancer
Novartis Pharmaceuticals 122